Capricor Therapeutics(CAPR)
Focus: Capricor Therapeutics is a San Diego-based public biotech specializing in allogeneic cell and exosome-based therapies for rare diseases, with a focus on cardiac and muscular dystrophy indications. The company operates at pre-revenue scale with an R&D-intensive model.
Profile data last refreshed 37m ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Capricor Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Capricor Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Capricor Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$22M
Pipeline & Clinical Trials
CAP-1002 Allogeneic Cardiosphere-Derived Cells
COVID-19Clinical Trials (1)
NCT04338347CAP-1002 in Severe COVID-19 Disease
N/AHelp build intelligence for Capricor Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.